Pfizer Inc. (PFE)
Pfizer, Inc. (PFE) Q3 2024 Earnings Call Transcript
Pfizer, Inc. (NYSE:PFE ) Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ET Company Participants Francesca DeMartino - Chief Investor Relations Officer & SVP Albert Bourla - Chairman & CEO Dave Denton - CFO Mikael Dolsten - Chief Scientific Officer and President of Research & Development Chris Boshoff - EVP & Chief Oncology Officer Alexandre de Germay - EVP & Chief International Commercial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Kripa Devarakonda - Truist Umer Raffat - Evercore Trung Huynh - UBS Louise Chen - Cantor Geoff Meacham - Citi Terence Flynn - Morgan Stanley Evan Seigerman - BMO Capital Markets Courtney Breen - Bernstein Steve Scala - TD Cowen Rajesh Kumar - HSBC Akash Tewari - Jefferies Vamil Divan - Guggenheim Securities Dave Risinger - Leerink Partners Chris Schott - JPMorgan Mohit Bansal - Wells Fargo Operator Good day, everyone, and welcome to Pfizer's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded.
Pfizer CEO Defends Record Against Activist Attack
Pfizer shares have performed abysmally in recent years, as the company has failed to win investor confidence ahead of a wave of patent expirations coming by the end of the decade.
Pfizer's Oncology Triumphs Keep Investors Hooked Amid Market Volatility
Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for the third quarter of 2024 by a large margin. Tafamidis franchise sales were $1.45 billion in Q3 2024, an increase of 9.4% quarter-on-quarter and 62.2% year-on-year. Meanwhile, sales of Padcev, approved for the treatment of urothelial cancer, amounted to $409 million for the three months ended September 30, 2024, an increase of 104.5% year-on-year.
Pfizer's Strong Quarter Bolsters CEO's Comeback Efforts
The pharmaceutical company reported its third consecutive quarter with positive results.
Pfizer Results May Temper Efforts for Shakeup Demanded by Activist Investor
Shares of Pfizer (PFE) fell Tuesday as a strong earnings report is seen as likely to limit activist investor Starboard Value from driving major changes at the drugmaker.
Pfizer Delivers Knockout Q3 Earnings Results, But Investors Are Unimpressed
Pfizer's Q3 earnings smashed analysts' expectations, driven by a significant increase in COVID-related revenues, but the market remains skeptical about long-term growth. Despite strong financials and upgraded 2024 guidance, Pfizer's stock is down 2% in trading today, reflecting concerns that COVID revenue gains are temporary. Non-COVID segments showed mixed results, with underwhelming performance in Primary Care and Oncology, and limited returns from recent M&A activities.
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
PFE beats third-quarter estimates for earnings and sales. It raises 2024 earnings and revenue expectations.
Pfizer (PFE) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to loss of $0.17 per share a year ago.
Pfizer ups guidance as demand for Covid-19 products grows
Pfizer Inc (NYSE:PFE, ETR:PFE) has lifted full-year revenue guidance on the back of a rebound in demand for its Covid-19 products. Revenue is expected to sit between $61 billion and $64 billion over the year, Pfizer said in third-quarter results on Tuesday, marking a $1.5 billion increase on previous expectations.
Pfizer Lifts Revenue Outlook, McDonald's Sees U.S. Sales Growth in Q3
Pfizer Q3 earnings beat expectations, driven by Paxlovid sales. Cost-saving goals aim for $4B by 2027 as Covid demand slows.
Pfizer's earnings crush estimates as company raises guidance
Drug company Pfizer saw strong growth for its heart-disease drugs and migraine treatment.
